Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
Retrieved on:
Wednesday, February 7, 2024
Science, Biotechnology, Research, Pharmaceutical, Surgery, Oncology, Health, Clinical Trials, Survival, Melanoma, Bristol Myers Squibb, Congress, NSCLC, EFS, PCR, Lung cancer, Patient, FDA, EMA, IIA, BMY, Food, ESMO, European Medicines Agency, Cancer, PDUFA, Bladder cancer, Checkmate, MPR, Pharmaceutical industry
Bristol Myers Squibb (NYSE: BMY) today announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).
Key Points:
- Bristol Myers Squibb (NYSE: BMY) today announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC).
- "Between 30% to 55% of non-small cell lung cancer patients who undergo surgery will experience disease recurrence.
- The study also showed benefits in key secondary endpoints including pathologic complete response (pCR) and major pathologic response (MPR).
- Opdivo and Opdivo-based combinations have shown efficacy benefits in the neoadjuvant, adjuvant or perioperative settings across four cancers to date, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma.